UIH(688271) 国盛证券·2024-12-23 00:29Investment Rating - The report maintains a "Buy" rating for the company [12][35]. Core Insights - The company is actively embracing the AI medical revolution, with significant investments in AI-driven medical imaging products and solutions [11][20][25]. - The investment in Lianying Intelligent is expected to enhance the company's product offerings with intelligent support, improving diagnostic assistance and data processing capabilities [25][34]. - The company has demonstrated strong growth in revenue and net profit, with a projected revenue of 105.18 billion yuan in 2024, despite a slight decline of 7.8% year-on-year [35]. Financial Summary - Revenue for 2022 was 9,238 million yuan, with a year-on-year growth of 27.4% [14]. - The projected revenue for 2023 is 11,411 million yuan, reflecting a growth rate of 23.5% [26]. - The expected net profit for 2024 is 15.63 billion yuan, with a year-on-year decrease of 20.8% [35]. - The company’s EPS for 2024 is projected to be 1.90 yuan, with a P/E ratio of 66 times [35]. - The company has maintained a strong financial position with a net profit margin of 17.9% in 2022 [14].